Unique Ingredient Identifier G2M7P15E5P is listed as a ingredient substance
| RN | 25322-68-3 |
| NCIT | C80131 |
| RXCUI | 221147 |
| MF | Polymer substance not supported |
UNII G2M7P15E5P POLYETHYLENE GLYCOL 3350 is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| INTRA-ARTERIAL | SUSPENSION, INJECTION | 29.1 mg/1mL |
| INTRA-ARTICULAR | INJECTION | 3 % |
| INTRALESIONAL | INJECTABLE | 2.91 % |
| INTRALESIONAL | INJECTION | 3 % |
| INTRALESIONAL | INJECTION, SUSTAINED ACTION | 2.9 % |
| INTRALESIONAL | SUSPENSION, INJECTION | 29.1 mg/1mL |
| INTRALESIONAL | SUSPENSION, INJECTION | 2.91 % |
| INTRAMUSCULAR | INJECTABLE | 2.91 %W/V |
| INTRAMUSCULAR | INJECTION | 6 %W/V |
| INTRAMUSCULAR | INJECTION, SUSPENSION | 2.89 % |
| INTRAMUSCULAR | INJECTION, SUSTAINED ACTION | 2.9 %W/V |
| INTRAMUSCULAR | SUSPENSION, INJECTION | 29.1 mg/1mL |
| INTRAMUSCULAR | SUSPENSION, INJECTION | 2.91 %W/V |
| INTRASYNOVIAL | INJECTABLE | 2.91 % |
| INTRASYNOVIAL | INJECTION | 3 % |
| INTRASYNOVIAL | INJECTION, SUSTAINED ACTION | 2.9 % |
| INTRASYNOVIAL | SUSPENSION, INJECTION | 2.91 % |
| INTRA-SYNOVIAL | SUSPENSION, INJECTION | 29.1 mg/1mL |
| NASAL | SOLUTION | 40 % |
| NASAL | SPRAY, METERED | 1.5 % |
| ORAL | CAPSULE | 27.2 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 0.67 MG |
| ORAL | CAPSULE, HARD GELATIN | 288 MG |
| ORAL | CAPSULE, SOFT GELATIN | 76.92 MG |
| ORAL | SUSPENSION | 45 MG/1ML |
| ORAL | SUSPENSION | 0.12 MG/15ML |
| ORAL | SUSPENSION, EXTENDED RELEASE | 9.31 MG/5ML |
| ORAL | SUSPENSION, SUSTAINED ACTION | NA |
| ORAL | TABLET | 25 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 9.7 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 15 MG |
| ORAL | TABLET, COATED | 0.5 MG |
| ORAL | TABLET, CONTROLLED RELEASE | 1.67 MG |
| ORAL | TABLET, DELAYED ACTION | 4.4 MG |
| ORAL | TABLET, DELAYED RELEASE | 2.43 mg |
| ORAL | TABLET, EXTENDED RELEASE | 20.2 MG |
| ORAL | TABLET, FILM COATED | 20 MG |
| ORAL | TABLET, FILM COATED | 2.42 MG |
| ORAL | TABLET, SUSTAINED ACTION | 6.75 MG |
| ORAL | TABLET, SUSTAINED ACTION, COATED | 8.5 MG |
| RECTAL | SUPPOSITORY | 1425.96 MG |
| SOFT TISSUE | INJECTION | 3 % |
| SOFT TISSUE | INJECTION, SUSTAINED ACTION | 2.9 % |
| SOFT TISSUE | SUSPENSION, INJECTION | 29.1 mg/1mL |
| SOFT TISSUE | SUSPENSION, INJECTION | 2.91 % |
| SUBCUTANEOUS | SUSPENSION, INJECTION | 4.42 % |
| TOPICAL | CREAM | 4.6 %W/W |
| TOPICAL | CREAM | 4.5 %W/W |
| TOPICAL | OINTMENT | 40 %W/W |
| VAGINAL | SUPPOSITORY | NA |